|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Missense mutations of A300V, V402M, and R415H in LNK were found in 8 patients including ET (4 cases, all combined with JAK2-V617F mutation), PV (2 cases, one combined with JAK2-V617F mutation), PMF (one case, combined with JAK2-V617F mutation) and CML (one case, combined with BCR/ABL1 fusion gene).
|
27111338 |
2016 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study.
|
21663510 |
2011 |
|
Myeloid Leukemia, Chronic
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that downmodulation of BCR/ABL gene expression could be one of the mechanisms involved in the response of CML patients to IFN-alpha treatment.
|
10498589 |
1999 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.
|
23009571 |
2012 |
|
Myeloid Leukemia, Chronic
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we found that the EVI1 activation in CML-BC is dependent on LEF1/β-catenin activation by BCR-ABL expression with loss of p53 function, representing a novel selective therapeutic approach targeting myeloid blast crisis progression.
|
27908728 |
2017 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
BCR-ABL1 tyrosine kinase inhibitors (TKIs) have dramatically transformed the treatment of patients with chronic myelogenous leukemia (CML).
|
27406834 |
2016 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Treatment with tyrosine kinase inhibitors (TKI) may sequentially induce TKI-resistant BCR-ABL mutants in chronic myeloid leukemia (CML).
|
28801986 |
2017 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
BCR-ABL kinase domain mutations are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients.
|
23409026 |
2013 |
|
Myeloid Leukemia, Chronic
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.
|
15109543 |
2004 |
|
Myeloid Leukemia, Chronic
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Longitudinal monitoring of BCR-ABL transcript levels in peripheral blood of CML patients treated with tyrosine kinase inhibitors (TKI) revealed a typical biphasic response.
|
30120281 |
2018 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance in patients with chronic myelogenous leukaemia.
|
20028401 |
2010 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The BCR-ABL1 fusion gene derived from the Philadelphia chromosome, resulting from a classical translocation event t(9;22)(q34.13;q11.23), is responsible for the pathogenesis of chronic myeloid leukemia (CML) in more than 90% of the patients.
|
28253493 |
2016 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The F- and G-actin binding region of the BCR/ABL C-terminus may be important in BCR/ABL-mediated events, and we have investigated this by expressing a C-terminus deletion mutant of the temperature-sensitive BCR/ABL PTK, in a haemopoietic progenitor cell line, which models the chronic phase of CML.
|
16487179 |
2006 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
The ABL insertion on chromosome 22 appears interstitial, similar to other cases of Ph-chromosome-negative CML.
|
2788468 |
1989 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
The BCR-ABL1 sequence has advantages over the BCR-ABL1 transcript as a molecular marker in chronic myeloid leukemia and has been used in research studies.
|
25554588 |
2015 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
LHGDN |
Our data support that in CML patients treated with STI571, ABL mutations are not restricted to the accelerated phase of the disease and that, at least in some cases, mutations seem to occur prior to STI571 therapy, probably as second mutational events during the course of CML.
|
12130516 |
2002 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
CLINVAR |
Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR-ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction.
|
22870928 |
2013 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
A reduction in <i>BCR-ABL1/ABL1<sup>IS</sup></i> transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients.
|
31064152 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
BCR-ABL1-negative myeloproliferative disorders and chronic myeloid leukaemia are haematologic malignancies characterised by single and mutually exclusive genetic alterations.
|
30965317 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib.
|
19878872 |
2009 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The quantitative real-time polymerase chain reaction (qRT-PCR) is used in the detection of molecular events involved in leukemogenesis, such as the Bcr-Abl gene translocation, the most important factor in the pathogenesis of chronic myeloid leukaemia (CML).
|
20658729 |
2010 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
LHGDN |
We have examined expression of MCL-1 in primary CML cells and BCR/ABL-transformed cell lines.
|
15626746 |
2005 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia.
|
22887688 |
2012 |
|
Myeloid Leukemia, Chronic
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The K562 BCR-ABL mRNA-positive cell line as well as bone marrow aspirates from 5 patients with chronic myelogenous leukemia (CML) and 5 controls without CML were used.
|
26148723 |
2015 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
After intravenous injection, CLANs carrying pCas9/gBCR-ABL (CLANpCas9/gBCR-ABL) efficiently knocked out the BCR-ABL fusion gene of CML cells and improved the survival of a CML mouse model, indicating that the combination of the CRISPR/Cas9 system with nanocarriers is a promising strategy for targeted treatment of CML.
|
29725684 |
2018 |